Integrated needle-free injection and sensing using opto-microfluidics

Informazioni relative al progetto

iSENS

ID dell’accordo di sovvenzione: 101158591

DOI

10.3030/101158591

Data della firma CE 11 Aprile 2024

Data di avvio 1 Luglio 2024

Data di completamento 30 Giugno 2027

Finanziato da

• The European Innovation Council (EIC)

Costo totale

€ 2 512 500,00

Contributo UE

€ 2 499 999,00

Coordinato da

FLOWBEAMS BV
Netherlands

Periodic Reporting for period 1 - iSENS (Integrated needle-free injection and sensing using opto-microfluidics)

Periodo di rendicontazione: 2024-07-01 al 2025-06-30

Sintesi del contesto e degli obiettivi generali del progetto

Needle-based injections have revolutionised healthcare by providing an efficient delivery method for medications, such as vaccines. However, there are significant drawbacks associated with using needles on a societal, environmental, and technological level. Needle phobia and infection risks can significantly impact patient compliance and safety with medical treatments, while millions of used needles contaminate the environment every day. Lastly, the effectiveness of certain drugs increases when injected intradermally, but targeting the dermis is challenging. With iSENS, we want to revolutionise the experience of people who receive and perform frequent injections. To this end, we are developing and commercialising a portable and needle-free injector called BoldJet. Through the technological breakthrough we present in this project safer, more effective, and minimally invasive injections that do not contaminate our environment. This patient-friendly technology will result in a positive effect on society, allowing millions of people to receive better and more personalised healthcare.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

Started different experimental work in our new lab facility. We have hired additional engineers to strengthen the technical team. Together with them we have been working on further development of the jetting and injection technology and related aspects. Furthermore, validation studies have been performed using our prototype device. On a regulatory and business perspective, we have improved our strategy and roadmap towards first market access. Most of the preliminary results are confidential and will be disclosed at a later stage.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

We set up a new office and lab facility for the FlowBeams team to work on the further development of the technology. The development of the injection technology has been speeded up. Collaboration with the University of Twente has led to two scientific manuscripts which are currently in preparation for publication.
From a business perspective, we gained more traction in the cosmetic industry, also emphasized by the CES Innovation Award 2025 in Beauty & Personal Care category.
As the project is still running, most of the preliminary results are confidential and will be disclosed at a later stage.

FlowBeams: Pioneering precise needle-free injection for a healthier world